Patents Examined by Melenie McCormick
-
Patent number: 9119826Abstract: The present invention provides a kit for the dietary management of cardiovascular patients with cardiovascular disease who are deficient in blood Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) levels, the kit including a diagnostic assay for determining blood levels of EPA, DHA and Docosapentaenoic acid (DPA) and a pharmaceutical grade prescription medical food omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of EPA, DPA and DHA in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA are about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition. The kit may further contain instructions for use of its components.Type: GrantFiled: August 13, 2012Date of Patent: September 1, 2015Assignee: Pivotal Therapeutics, Inc.Inventors: George Jackowski, Rachelle MacSweeney, Nisar Shaikh, Jason Yantha, Valerie Schini-Kerth
-
Patent number: 9101632Abstract: The invention provides kinase inhibitors of Formula I: wherein either: (1) R1 is H, and (a) R2 is (3-chlorobenzyl)oxy-and R3 is chloro; (b) R2 and R3, together with the carbon atoms to which they are attached, form 1-(3-fluorobenzyl)-1H-pyrazole; (c) R2 is 2-pyridinylmethoxy and R3 is chloro; (d) R2 and R3 are both chloro; (e) R2 is chloro and R1 is bromo; (f) R2 and R3 are both bromo; (g) R2 is fluoro and R3 is ethynyl; (h) R2 is chloro and R3 is ethynyl; (i) R2 is bromo and R3 is ethynyl; (j) other than when R1 is in the 3-position in combination with R3, in the 4-position, R2 is bromo and R3 is fluoro; (k) R2 is 2-pyridinylmethoxy and R3 is fluoro; or (l) R2 is 2-pyridinylmethoxy and R1 is bromo; or (2) at least one of R1, R2 and R3 is selected from benzyloxy, 3-chlorobenzyloxy and 2-pyridinylmethoxy and when at least one of R1, R2 and R3 is not benzyloxy, 3-chlorobenzyloxy or 2-pyridinylmethoxy, each of the others is independently selected from H, halogen, and C2-C4 alkynyl, with the proviso thatType: GrantFiled: September 2, 2010Date of Patent: August 11, 2015Assignee: AUCKLAND UNISERVICES LIMITEDInventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Guo-Liang Lu, Ho Huat Lee, Amir Ashoorzadeh, Robert Forbes Anderson, William Robert Wilson, William Alexander Denny, Huai-Ling Annie Hsu, Andrej Maroz, Stephen Michael Frazer Jamieson, Alexandra Marie Mowday, Kendall Marie Carlin
-
Patent number: 9089129Abstract: A non-aerosol, foaming high alcohol content hand sanitizer is provided which has excellent antimicrobial activity and tolerance for organic load and excellent residual activity, as well as enhanced moisturization and skin-feel properties over currently marketed alcohol-based sanitizers. The inventive composition achieves an unexpectedly large amount of quality, stable foam even in the presence of significant quantities of skin conditioning agents through the use of novel silicone surfactants and achieves enhanced and prolonged antimicrobial efficacy through the combination of high alcohol content and activity enhancing components.Type: GrantFiled: October 4, 2012Date of Patent: July 28, 2015Assignee: AMERICAN STERILIZER COMPANYInventors: Christopher C. Heisig, Nancy-Hope E. Kaiser
-
Patent number: 9072747Abstract: A topical anorectal composition includes trimethylsiloxysilicate; at least one surfactant selected from the group consisting of sodium lauryl sulfate, alkyl- and alkoxy-dimethicone copolyol, polysorbate and a combination thereof; a non-polar volatile siloxane solvent; at least 15% (w/w) water; and a pharmaceutical agent selected from the group consisting of pramoxine, phenylephrine, hydrocortisone, salicylic acid, nitroglycerine, sildenafil, or their salts and combinations thereof, wherein the composition is sufficiently designed to dry within 60 seconds after application to the anorectal mucosa to form a dried composition, and wherein the dried composition forms: a flexible film, wherein the flexible film closely follows irregularities of the body surface as well as movement of the body surface, and (ii) a durable film, wherein the durable film does not crack or flake off and remains intact for more than 12 hours giving release of the pharmaceutical agent for an extended period of time.Type: GrantFiled: March 10, 2014Date of Patent: July 7, 2015Assignee: PERITECH PHARMA LTD.Inventors: Evgenia Lozinsky, Eran Eilat
-
Patent number: 8980867Abstract: Suggested are biocide compositions, comprising (a) Alkoxylated oligoglycerol esters; (b) Biocides and optionally (c) Oil components or co-solvents and/or (d) Emulsifiers. The compositions show excellent adjuvant properties.Type: GrantFiled: March 30, 2011Date of Patent: March 17, 2015Assignee: Cognis IP Management GmbHInventors: Hans-Georg Mainx, Sandra Mack, Ingo Fleute-Schlachter
-
Patent number: 8969327Abstract: The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.Type: GrantFiled: April 7, 2011Date of Patent: March 3, 2015Assignees: Emory University, The Research Foundation of State of New York, Hauptman-Woodward Medical Research InstituteInventors: Huw Davies, Dabashis Ghosh, Daniel Morton
-
Patent number: 8969337Abstract: The present invention relates to compounds of Formula I:Type: GrantFiled: December 14, 2012Date of Patent: March 3, 2015Assignee: Alkermes Pharma Ireland LimitedInventors: Laura Cook Blumberg, John A. Lowe, Orn Almarsson, Juan Alvarez, Tarek A. Zeidan
-
Patent number: 8962662Abstract: This disclosure provides generally for antimicrobial compositions and methods for reducing or preventing microorganism growth, viability, or survival, which are useful for treating poultry, meat, seafood, vegetables, legumes, fruit, crops, and other products for human or animal consumption. For example, the compositions can include GRAS (Generally Recognized As Safe) antimicrobial components such as ?-poly-L-lysine in combination with at least one quaternary ammonium salt, including an aliphatic heteroaryl ammonium salt such as cetylpyridinium chloride.Type: GrantFiled: November 13, 2012Date of Patent: February 24, 2015Assignee: Byocoat Enterprises, Inc.Inventors: Fredrick Busch, Steve R. Burwell, Mark O'Reilly
-
Method for post coital contraception in overweight or obese female subjects using ulipristal acetate
Patent number: 8962603Abstract: The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese.Type: GrantFiled: December 1, 2010Date of Patent: February 24, 2015Assignee: Laboratoire HRA-PharmaInventors: Delphine Levy, Andre Ulmann, Henri Camille Mathe, Erin Gainer -
Patent number: 8957053Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: GrantFiled: January 7, 2014Date of Patent: February 17, 2015Assignees: Tesorx Pharma, LLC, Western University Health SciencesInventors: Guru V. Betageri, Ramachandran Thirucote, Veeran Gowda Kadajji
-
Patent number: 8940757Abstract: The present invention relates to Prasugrel or a pharmaceutically acceptable salt thereof, compositions containing said active ingredient as well as pharmaceutical compositions containing said active ingredient or a composition containing said active ingredient. The present invention further relates to methods for the preparation of the novel compositions.Type: GrantFiled: February 10, 2011Date of Patent: January 27, 2015Assignee: ratiopharm GmbHInventors: Sandra Brueck, Jana Paetz
-
Patent number: 8937081Abstract: A composition for increasing the bioavailability of a statin active pharmaceutical ingredient (“API”) in humans and animals, wherein that composition includes a statin API selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the first surfactant and the second surfactant comprises a cloud point less than about 37° C.Type: GrantFiled: December 12, 2012Date of Patent: January 20, 2015Assignee: PruGen IP Holdings, Inc.Inventor: Bhiku G. Patel
-
Patent number: 8937176Abstract: This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.Type: GrantFiled: December 10, 2012Date of Patent: January 20, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Klaus Rudolf, Daniel Bischoff, Georg Dahmann, Matthias Grauert, Raimund Kuelzer
-
Patent number: 8927550Abstract: Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).Type: GrantFiled: October 21, 2010Date of Patent: January 6, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Brian Nicholas Cook, Daniel Kuzmich
-
Patent number: 8927607Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.Type: GrantFiled: August 22, 2013Date of Patent: January 6, 2015Assignee: Hikma Pharmaceuticals LLCInventor: Murray Ducharme
-
Patent number: 8927586Abstract: The present invention relates to novel TP receptor antagonists, which optionally cross the blood-brain barrier of a mammal. The invention also provides methods for treating a disorder related to activation of TP receptor utilizing the compounds of the invention.Type: GrantFiled: February 28, 2013Date of Patent: January 6, 2015Assignee: The Trustees of the University of PennsylvaniaInventors: John Q. Trojanowski, Virginia M. Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huym, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli, Sugiyama Shimpei, Xiaozhao Wang
-
Patent number: 8916705Abstract: The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.Type: GrantFiled: October 15, 2012Date of Patent: December 23, 2014Assignee: The Board of Trustees of the University of IllilnoisInventor: Paul J. Hergenrother
-
Patent number: 8916545Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.Type: GrantFiled: August 3, 2012Date of Patent: December 23, 2014Assignee: Neonc Technologies Inc.Inventors: Thomas Chen, Daniel Levin, Satish Pupalli
-
Patent number: 8907103Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.Type: GrantFiled: August 13, 2009Date of Patent: December 9, 2014Assignee: Metabasis Therapeutics, Inc.Inventors: Jorge E. Gomez-Galeno, Scott J. Hecker, Qun Dang, Mali Venkat Reddy, Zhili Sun, Matthew P. Grote, Thanh Huu Nguyen, Robert Huerta Lemus, Haiqing Li
-
Patent number: 8895611Abstract: The cytotoxic compounds are gold(III) complexes of the type [(diaminocyclohexane)AuCl2]Cl, derived from sodium tetrachloroaurate(III) dihydrate NaAuCl4.2H2O. Specifically, the cytotoxic compounds are gold complexes of isomers of 1,2-diaminocyclohexane, namely cis-(±)-1,2-(diaminocyclohexane)AuCl3, trans-(±)-1,2-(diaminocyclohexane)AuCl3 and S,S-(+)-1,2-(diaminocyclohexane)AuCl3. In order to treat cancer cells in a patient, such as human prostate cancer cells or human gastric cancer cells, an effective amount of the isomer of 1,2-(diaminocyclohexane)AuCl3 is administered to the cancer cells in the patient. The isomer of 1,2-(diaminocyclohexane)AuCl3 is preferably administered with a concentration ranging between about 10 ?M and 20 ?M.Type: GrantFiled: July 17, 2013Date of Patent: November 25, 2014Assignees: King Fahd University of Petroleum and Minerals, King Abdulaziz City for Science and TechnologyInventors: Anvarhusein Abdulkadir Isab, Mohammed Ismail Mohammed Wazeer, Said Salman Al-Jaroudi, Saleh Abdulaziz Altuwaijri